Baystreet.ca - Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs - Completion of Initial DMT Research Drug Batch and Exercise of Warrants Vancouver Canada based Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement with Psygen Labs Inc. Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quali...
Source: baystreet.ca